Published in PLoS One on December 05, 2013
Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) | NCT03476070
Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer (2015) 0.92
Monitoring and optimising cognitive function in cancer patients: Present knowledge and future directions. EJC Suppl (2014) 0.91
Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol (2015) 0.90
Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment--the role of fatigue. Neuroimage Clin (2015) 0.88
Modifiable factors and cognitive dysfunction in breast cancer survivors: a mixed-method systematic review. Support Care Cancer (2015) 0.80
Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine. Cancer Biol Ther (2014) 0.79
Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One (2017) 0.75
Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. PLoS One (2016) 0.75
A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients. Springerplus (2016) 0.75
Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia. Cancer (2017) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom (2004) 3.52
Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol (2008) 3.30
Changes in proinflammatory cytokine activity after menopause. Endocr Rev (2002) 3.24
Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer (2007) 3.12
Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol (2010) 3.09
The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04
Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry (2000) 2.96
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Cytokines and cognition--the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc (2002) 2.79
Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol (2005) 2.70
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol (2003) 2.64
Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol (2010) 2.52
The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun (2006) 2.40
The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab (2004) 2.34
Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol (2012) 2.33
Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev (2008) 2.30
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer (2005) 2.09
ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci (2008) 2.09
International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol (2011) 2.06
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol (2012) 1.99
Role and therapeutic potential of VEGF in the nervous system. Physiol Rev (2009) 1.98
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol (2004) 1.89
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry (2008) 1.85
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv (2009) 1.81
Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci (1992) 1.78
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine (2004) 1.70
Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol (2002) 1.67
Inflammation: a new candidate in modulating adult neurogenesis. J Neurosci Res (2008) 1.55
Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun (2012) 1.48
Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun (2008) 1.42
Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol (2004) 1.41
Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun (2012) 1.40
Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J Immunol Methods (2006) 1.39
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol (2002) 1.37
Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain (1997) 1.37
Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev (2010) 1.33
Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol (2008) 1.33
Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res (2012) 1.32
Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology (2010) 1.32
Age-related neuroinflammatory changes negatively impact on neuronal function. Front Aging Neurosci (2010) 1.31
How sleep deprivation affects psychological variables related to college students' cognitive performance. J Am Coll Health (1997) 1.29
Neurocognitive changes in cancer survivors. Cancer J (2008) 1.27
Renaming "chemobrain". Cancer Invest (2007) 1.22
Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis (2006) 1.22
Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med J (2005) 1.21
Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging (1995) 1.20
Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation (2003) 1.18
Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. Cancer Res (2011) 1.16
Cytokine quantitation: technologies and applications. Front Biosci (2007) 1.13
CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol (1997) 1.13
Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol (1986) 1.12
Cognitive function in breast cancer survivors. Cancer Treat Res (2009) 1.12
Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res (2005) 1.10
Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology (2010) 1.09
Women's perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs (2010) 1.09
Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience (2010) 1.09
Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem (2007) 1.08
Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer (2011) 1.07
Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol (2006) 1.04
Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) (2008) 1.04
Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol (2010) 1.02
Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain. J Neurosci Res (2007) 1.00
Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage (2010) 1.00
2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med (2011) 1.00
Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy? Trends Pharmacol Sci (2003) 0.99
Decreased attentional responsivity during sleep deprivation: orienting response latency, amplitude, and habituation. Sleep (1997) 0.98
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta (2006) 0.95
Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res (2009) 0.93
Amplitude reduction in visual event-related potentials as a function of sleep deprivation. Sleep (1999) 0.92
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 0.90
Levels of tumor necrosis factor alpha, interleukin 6, interleukin 10, and transforming growth factor beta are normal in the serum of the healthy elderly. Clin Infect Dis (1994) 0.89
Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology (Berl) (2011) 0.88
The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res (2012) 0.88
Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat (2011) 0.88
Cytokines and advanced cancer. J Pain Symptom Manage (2000) 0.88
A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog'). J Clin Pharm Ther (2010) 0.86
The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol (2010) 0.85
Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol (2012) 0.82
Chemotherapy-induced cognitive dysfunction: a clearer picture. Clin Breast Cancer (2003) 0.82
Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol (1998) 0.82
Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncol Nurs Forum (2008) 0.81
Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol (2011) 0.81
Partial androgen deficiency, depression, and testosterone supplementation in aging men. Int J Endocrinol (2012) 0.80
Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav (2011) 0.77
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer (2011) 1.78
Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther (2008) 1.26
Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev (2013) 1.18
Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol (2011) 1.17
Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother (2008) 1.15
Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther (2014) 1.15
Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature. Onkologie (2012) 1.14
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer (2013) 1.10
Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab (2006) 1.07
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol (2010) 1.05
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04
A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol (2010) 1.02
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev (2012) 0.97
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem Res Toxicol (2007) 0.94
Nanomaterial scaffolds for stem cell proliferation and differentiation in tissue engineering. Biotechnol Adv (2012) 0.93
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother (2009) 0.92
Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer (2014) 0.92
Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother (2009) 0.91
Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer (2014) 0.89
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol (2013) 0.89
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat (2012) 0.88
Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. J Clin Psychopharmacol (2012) 0.88
Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. Expert Opin Drug Saf (2013) 0.87
An investigation of the bioactivation potential and metabolism profile of Zebrafish versus human. J Biomol Screen (2012) 0.87
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol (2014) 0.85
Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Mol Cancer (2012) 0.85
Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. Lancet Oncol (2009) 0.84
Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer (2014) 0.84
Clinical outcomes for cancer patients using complementary and alternative medicine. Altern Ther Health Med (2012) 0.83
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol (2015) 0.83
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. Cancer Chemother Pharmacol (2012) 0.83
Feasibility and acceptance of a pharmacist-run tele-oncology service for chemotherapy-induced nausea and vomiting in ambulatory cancer patients. Telemed J E Health (2013) 0.83
Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. Pharmacoepidemiol Drug Saf (2013) 0.82
Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther (2012) 0.82
Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric (2010) 0.82
Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials (2013) 0.82
Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian patients with breast cancer. Value Health (2013) 0.82
Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Support Care Cancer (2014) 0.81
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol (2011) 0.81
An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer (2009) 0.81
Exploring clinical determinants and anxiety symptom domains among Asian breast cancer patients. Support Care Cancer (2013) 0.81
Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol (2011) 0.81
Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. Int J Clin Pharm (2013) 0.80
Global gas chromatography/time-of-flight mass spectrometry (GC/TOFMS)-based metabonomic profiling of lyophilized human feces. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.80
Minimum qualifications for clinical pharmacy practice faculty. Pharmacotherapy (2014) 0.80
Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia. J Cancer Surviv (2013) 0.80
OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. Int J Qual Health Care (2010) 0.79
Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. Acta Haematol (2010) 0.79
Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study. Asian Pac J Cancer Prev (2016) 0.79
Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol Lett (2009) 0.79
Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicol Lett (2010) 0.79
Technological preferences of aging cancer patients for delivery services and devices to solve drug-related problems in oncology. Support Care Cancer (2014) 0.79
Interaction of lapatinib with cytochrome P450 3A5. Drug Metab Dispos (2012) 0.78
Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother (2012) 0.78
Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol (2010) 0.78
Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol (2009) 0.78
Cancer informatics for the clinician: an interaction database for chemotherapy regimens and antiepileptic drugs. Seizure (2009) 0.77
Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties. Eur J Pharmacol (2012) 0.77
An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer (2012) 0.77
Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies. Curr Opin Support Palliat Care (2016) 0.77
To SMILE or not: supportive care matters. J Clin Oncol (2012) 0.76
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease. J Med Chem (2015) 0.76
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol (2014) 0.76
Correction: The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review. PLoS One (2015) 0.75
Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. Medicine (Baltimore) (2016) 0.75
Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. Toxicol Res (2012) 0.75
Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective. J Clin Oncol (2011) 0.75
Pulmonary edema and possible pneumonitis associated with celecoxib. Ann Pharmacother (2004) 0.75
Survivorship Care Provision for Patients With Hematologic Malignancies: The Quest for Quality Evidence. Cancer Nurs (2015) 0.75
Detection and management of oncology drug interactions: Can we do better? Maturitas (2009) 0.75
Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories. J Oncol Pharm Pract (2010) 0.75
Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines. J Altern Complement Med (2012) 0.75
Recommendations for Aligning PGY2 Pharmacy Residency Training and Pharmacy Specialist Board Certification. Pharmacotherapy (2016) 0.75
Immobilisation of quantum dots by bio-orthogonal PCR amplification and labelling for direct gene detection and quantitation. Chem Commun (Camb) (2012) 0.75
Mitochondria-acting hexokinase II peptides carried by short-length carbon nanotubes with increased cellular uptake, endosomal evasion, and enhanced bioactivity against cancer cells. Nanoscale (2015) 0.75
Experience with nesiritide at a community hospital. Am J Health Syst Pharm (2004) 0.75
Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians. Eur Neurol (2010) 0.75
Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center. Clin Ther (2012) 0.75
Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI. Inform Health Soc Care (2011) 0.75
Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract (2012) 0.75
Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation. Toxicol Lett (2011) 0.75